http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-068020-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_510323630d544033a0dd3d722dd566a1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-852 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| filingDate | 2008-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41cc4be8b8cd271408b701b9e9323b50 |
| publicationDate | 2009-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-068020-A1 |
| titleOfInvention | COMBINED THERAPY FOR PANCREAS CANCER USING AN ANTIGEN PEPTIDE AND A CHEMOTHERAPEUTIC AGENT |
| abstract | Combined therapy appropriate for the treatment of pancreatic cancer, and similar, and a method to enhance the therapeutic effect of chemotherapeutic agents such as gemcitabine. Claim 1: A method of treating a cancer in a subject characterized in that it comprises administering to said subject (i) and (ji): (i) one or more peptides selected from the group consisting of (a) one or more peptides having a amino acid sequence selected from the group consisting of RFVPDGNRI (SEQ ID Ns 1), VYSSEEAEL (SEQ ID Ns 2), GYRIYDVVL (SEQ ID Ns 3), SYMISYAGM (SEQ ID Ns 4), KWEFPRDRL (SEQ ID Ns 5) and DFLTLEHLI (SEQ ID Ns 6), (b) the peptide of (a), where 1, 2 or several amino acids have been substituted, deleted or added, and where said peptide can induce cytotoxic T cells; (c) the peptide of (b), where the second amino acid from the N-terminus is phenylalanine, tyrosine, methionine or tryptophan; (d) the peptide of (b) or (c), where the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan or methionine; (e) one or more peptides having an amino acid sequence selected from the group consisting of AMFFWLLLV (SEQ ID Ns 7), VIAMFFWLL (SEQ ID Ns 8), AVIAMFFWL (SEQ ID Ns 9), KLIEIGVQT (SEQ ID Ns 10) , YMISYAGMV (SEQ ID Ns 11), IQSDVWSFGV (SEQ ID Ns 12) and VLAMFFWLL (SEQ ID Ns 13); (f) the peptide of (e), where 1, 2 or several amino acids have been substituted, deleted or added, and where said peptide can induce cytotoxic T cells; (g) the peptide of (f), where the second amino acid from the N-terminus is leucine or methionine; and (h) the (f) or (g) peptide, where the C-terminal amino acid is valine or leucine; (ii) one or more chemotherapeutic agents selected from the group consisting of gemcitabine, a salt acceptable for pharmaceutical use thereof and a prodrug thereof. |
| priorityDate | 2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.